We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Real-world experience with letermovir in primary prophylaxis of cytomegalovirus in adult patients after hematopoietic cell transplantation: summary of reported data.
- Authors
Czyżewski, Krzysztof; Styczyński, Jan
- Abstract
Introduction: Letermovir (LMV) is a new antiviral agent approved in 2017 for prophylaxis to prevent cytomegalovirus (CMV) reactivation in CMV-seropositive allogeneic hematopoietic cell transplant recipients. Numerous reports on real--world experiences with LMV have been presented at international hematology and hematopoietic cell transplantation meetings. The objective of this study was to summarize data reported 2019-2020 on primary prophylaxis with LMV in adult patients. Methods: We analyzed 19 studies published or presented in 2019 and 2020, including two studies presented twice. Results: An overall 817 patients received primary prophylaxis with LMV. In 12 studies with a control group, the rate of breakthrough infection was 99/577 (17.2%) vs. 874/1,525 (57.3%), odds ratio (OR) =6.5 [95% confidence interval (CI) =5.1-8.2), p <0.0001]. In seven studies without a control group, the rate was 17/240 (7.1%). Overall breakthrough infection occurred in 116/817 (14.2%) patients on LMV primary prophylaxis vs. 874/1,525 (57.3%) without prophylaxis, OR =8.1 (95% CI =6.5-10.1), p <0.0001. Conclusions: LMV when used for primary prophylaxis challenges the standard of care for CMV reactivation based on preemptive therapy. Presented real-world data shows a significant improvement in reducing the risk of any CMV viremia and clinically significant CMV infection in all reported studies performed so far. LMV is a drug that breaks the paradigm of preventive therapy by moving it from pre-emptive treatment to prophylaxis.
- Subjects
ANTIVIRAL agents; ANTI-infective agents; PREVENTIVE medicine; CYTOMEGALOVIRUS disease treatment; CYTOMEGALOVIRUS disease diagnosis
- Publication
Acta Haematologica Polonica, 2021, Vol 52, Issue 3, p182
- ISSN
0001-5814
- Publication type
Article
- DOI
10.5603/AHP.2021.0035